Amylyx Pharmaceuticals (AMLX) Leases (2022 - 2025)
Amylyx Pharmaceuticals (AMLX) has 4 years of Leases data on record, last reported at $5.2 million in Q4 2025.
- For Q4 2025, Leases rose 192.55% year-over-year to $5.2 million; the TTM value through Dec 2025 reached $5.2 million, up 192.55%, while the annual FY2025 figure was $5.2 million, 192.55% up from the prior year.
- Leases reached $5.2 million in Q4 2025 per AMLX's latest filing, down from $5.5 million in the prior quarter.
- Across five years, Leases topped out at $6.8 million in Q1 2022 and bottomed at $1.3 million in Q1 2025.
- Average Leases over 4 years is $4.6 million, with a median of $5.1 million recorded in 2023.
- The widest YoY moves for Leases: up 192.55% in 2025, down 61.38% in 2025.
- A 4-year view of Leases shows it stood at $5.5 million in 2022, then crashed by 32.57% to $3.7 million in 2023, then crashed by 52.46% to $1.8 million in 2024, then surged by 192.55% to $5.2 million in 2025.
- Per Business Quant database, its latest 3 readings for Leases were $5.2 million in Q4 2025, $5.5 million in Q3 2025, and $5.8 million in Q2 2025.